Valuation: Everest Organics Limited

Market Cap 1.98B 20.65M 17.69M 16.55M 15.15M 28.43M 28.81M 196M 76.25M 992M 77.53M 75.85M 3.28B P/E 2024
675x
P/E 2025 -190x
Enterprise Value 2.39B 24.96M 21.38M 20M 18.31M 34.36M 34.82M 236M 92.16M 1.2B 93.71M 91.68M 3.97B EV / Sales 2024
0.75x
EV / Sales 2025 1.79x
Free-Float
23.1%
Yield 2024 *
-
Yield 2025 -
1 day-3.62%
1 week+3.04%
Current month-0.77%
1 month-3.33%
3 months+14.54%
6 months-19.32%
Current year-41.12%
1 week 250
Extreme 250
333
1 month 250
Extreme 250
339
Current year 197
Extreme 197
536.4
1 year 197
Extreme 197
536.4
3 years 106.2
Extreme 106.2
536.4
5 years 95
Extreme 95
536.4
10 years 44.45
Extreme 44.45
536.4
Manager TitleAgeSince
Chief Executive Officer 48 -
Director of Finance/CFO 59 2015-09-27
Director TitleAgeSince
Director/Board Member 71 2024-11-12
Director/Board Member 47 2007-09-28
Director/Board Member 48 2014-07-29
Change 5-day change 1-year change 3-year change Capi.($)
-3.62%+3.04%-27.70%+151.10% 31.36M
-0.08%-1.43%+15.99%+67.26% 47.74B
-3.21%+1.37%+52.36%+125.75% 41.7B
-0.40%-1.23%-10.08%+16.08% 12.14B
+1.11%-1.34%+13.61%+71.49% 11.55B
0.00%+0.58%+30.65%+148.80% 9.18B
-0.39%-0.92%+19.81%+39.54% 7.54B
-1.35%+0.74%+47.03%-11.93% 7.35B
-0.64%-0.02%+19.42%+199.06% 6.88B
-5.36%-6.36%-36.28%+18.28% 5.72B
Average -1.39%-0.97%+12.48%+82.54% 14.98B
Weighted average by Cap. -1.19%-0.77%+24.58%+83.63%

Financials

2024 2025
Net sales 1.98B 20.7M 17.73M 16.59M 15.18M 28.5M 28.87M 196M 76.43M 995M 77.71M 76.02M 3.29B 1.6B 16.72M 14.32M 13.4M 12.27M 23.02M 23.32M 158M 61.74M 804M 62.77M 61.41M 2.66B
Net income 1.39M 14.55K 12.46K 11.66K 10.67K 20.03K 20.3K 138K 53.73K 699K 54.63K 53.44K 2.31M -12.9M -135K -116K -108K -98.94K -186K -188K -1.28M -498K -6.48M -506K -495K -21.44M
Net Debt 570M 5.95M 5.1M 4.77M 4.37M 8.2M 8.31M 56.38M 21.98M 286M 22.35M 21.87M 946M 412M 4.31M 3.69M 3.45M 3.16M 5.93M 6.01M 40.81M 15.92M 207M 16.18M 15.83M 685M
Logo Everest Organics Limited
Everest Organics Limited is engaged in the business of manufacturing of active pharmaceutical ingredients (API) and intermediaries. It is involved in the manufacturing of bulk drugs. The Company’s API products include Omeprazole, Pantoprazole Sodium Sesquihydrate, Esomeprazole Magnesium Trihydrate, Esomeprazole Magnesium Dihydrate, Esomeprazole Sodium, Omeprazole Sodium, Omeprazole Magnesium, Fenofibrate, Tamsulosin Hcl, and Dexlansoprazole. Its products under development include Remdesivir, Molnupiravir, Carbidopa, Acotiamide HCL, and Apixaban. Its intermediates products include Ethyl 2-(4-Hydroxyphenyl)-4-Methyl-5-Thiazolecarboxylate, Ethyl 2-(3-Formyl-4-Hydroxyphenyl)-4-Methylthiazole-5- Carboxylate, Ethyl 2-(3-Formyl-4-Isobutoxyphenyl)-4-Methylthiazole-5-Carboxylate, Ethyl 2-(3-Cyano-4-Isobutoxyphenyl)-4-Methyl-5- Thiazolecarboxylate, 2-Chloromethyl-4-Methoxy-3-Methyl-Pyridine Hydrochloride, and 5-(1H-Pyroll-1-yl)-2-Mercaptobenzimidazole, among others.
Employees
355
Date Price Change Volume
26-08-21 ₹297.80 -3.62% 568
26-08-20 ₹309.00 +4.22% 37
26-08-19 ₹296.50 -6.58% 3,439
26-08-18 ₹317.40 +10.61% 12,002
26-08-17 ₹286.95 -0.71% 1,014
  1. Stock Market
  2. Stocks
  3. EVERESTO6 Stock